Mission

Maximize therapeutic effectiveness/risk ratio and patient acceptance via non- and minimally-invasive drug delivery technologies

Overview

The Advanced Drug Delivery group at BD Technologies is researching novel and proprietary delivery technologies designed to enhance the therapeutic value and convenience of vaccine and drug delivery. Over the past 100 years, BD has developed a wealth of knowledge about effective parenteral drug delivery. BD Technologies, working alone and partnering with pharmaceutical and biotechnology companies and government research organizations, has applied its technology to the next frontiers of drug and vaccine science.

Platform Technology

Microneedle Delivery Technology for Cutaneous Administration

Based upon pre-clinical and clinical experience with over 30 therapeutic agents and vaccines, BD has extensive expertise in microneedle-based administration of pharmaceutical agents. One notable recent example is microneedle-based delivery of a next generation Anthrax vaccine. Researchers at BD Technologies and the US Army Medical Research Institute of Infectious Diseases have published a study in The Journal of Infectious Diseases ("Protective Immunization against Inhalational Anthrax: A Comparison of Minimally Invasive Delivery Platforms", 2005:191, January15, 2005) which demonstrates in preclinical challenge studies that microneedle-based delivery of this vaccine results in complete protection against inhalational anthrax. BD is also investigating other applications of this microneedle technology in defense settings. Further, this technology may be applicable to many commercial therapeutic and diagnostic areas including the treatment of diabetes, HIV and cancer as well as other fields of vaccination.

The technology is described in issued patents directed to intradermal delivery as well as devices useful for achieving such intradermal delivery. BD also owns pending patent applications that describe intradermal delivery of particular drugs and vaccines as well as techniques for achieving improved effects through the intradermal delivery of those drugs and vaccines.

Potential Benefits:

• Reduced pain perception
• Improved pharmacokinetic and bioavailability profiles
• Application to small molecules, large molecules and vaccines

Return to top of page